Cannabis Law Report

AUGUST 24, 2021

BALTIMORE–(BUSINESS WIRE)– $MYMD — MyMD Pharmaceuticals, Inc. About MyMD Pharmaceuticals, Inc. MyMD Pharmaceuticals, Inc. The Company’s second drug platform, Supera-CBD, is being developed to treat chronic pain, addiction and epilepsy.

Pharmaceutical 98

Pharmaceutical Clinical Trials Chronic Pain CBD 98

MMJ Recs

APRIL 1, 2024

Studies have suggested that CBD may help manage chronic pain, reduce anxiety and depression, alleviate symptoms of epilepsy, and even aid in cancer treatment. Furthermore, ongoing clinical trials are investigating CBD’s efficacy in treating conditions such as multiple sclerosis, Parkinson’s disease, and substance abuse disorders.

CBD 52

CBD Clinical Trials Chronic Pain Epilepsy 52

Cannabis Law Report

DECEMBER 1, 2021

BALTIMORE–(BUSINESS WIRE)– MyMD Pharmaceuticals, Inc. Nasdaq: MYMD) (“MyMD” or “the Company”), a clinical stage pharmaceutical company committed to extending healthy lifespan by delaying aging, today announced that it will participate in two investor conferences during the month of December 2021. About Supera-CBD.

Pharmaceutical 52

Pharmaceutical Clinical Trials Chronic Pain Therapy 52

Cannabis Law Report

SEPTEMBER 24, 2019

Here is the BBC report and below you will find the full press release from GW Pharmaceuticals. T he EU has approved for the first time the use of a medicinal cannabis product aimed at patients with two rare, but severe, forms of childhood epilepsy. What about other medical cannabis products? What do experts say? September 23, 2019.

Pharmaceutical 55

Pharmaceutical Epilepsy Research and Development Medicine 55

Cannabis Law Report

OCTOBER 26, 2021

BALTIMORE–(BUSINESS WIRE)– MyMD Pharmaceuticals, Inc. Nasdaq: MYMD) (“MyMD” or “the Company”), a clinical stage pharmaceutical company committed to extending healthy lifespan, announced today that Chris Chapman, M.D., Chapman has operated Chapman Pharmaceutical Consulting, Inc., MyMD Pharmaceuticals, Inc.

Pharmaceutical 52

Pharmaceutical Clinical Trials Research and Development Therapy 52

Cannabis Law Report

OCTOBER 5, 2021

MyMD to launch two simultaneous Phase 2 trials during the current quarter to study MYMD-1’s function in extending healthy lifespan and treating COVID-19-associated depression. BALTIMORE–(BUSINESS WIRE)– MyMD Pharmaceuticals, Inc. About MyMD Pharmaceuticals, Inc. MyMD Pharmaceuticals, Inc.

Pharmaceutical 52

Pharmaceutical Clinical Trials Chronic Pain Media 52

Cannabis Law Report

SEPTEMBER 22, 2021

New data will be presented at the 4th Annual International Cannabinoid-Derived Pharmaceuticals Summit in Boston. BALTIMORE–(BUSINESS WIRE)– MyMD Pharmaceuticals, Inc. We believe that the new data we are revealing today is an extraordinary achievement in the field of pharmaceutical cannabinoids,” said Adam Kaplin, M.D.,

Pharmaceutical 52

Pharmaceutical Data CBD Clinical Trials 52

Cannabis Law Report

OCTOBER 19, 2021

BALTIMORE–(BUSINESS WIRE)– MyMD Pharmaceuticals, Inc. Nasdaq: MYMD) (“MyMD” or “the Company”), a clinical stage pharmaceutical company committed to extending healthy lifespan, announced today that it will present at the Dawson James Securities 6th Annual Small Cap Growth Conference on Thursday, October 21, 2021, at 4:30 p.m.

Pharmaceutical 52

Pharmaceutical Therapy Clinical Trials Chronic Pain 52

TheAnswerPage

JUNE 29, 2022

Has CBDV been evaluated as an anti-seizure medication in clinical trials? Yes, GW Pharmaceuticals (the makers of Epidiolex) had trialed CBDV in adult epilepsy, but the study did not meet its primary endpoint of seizure reduction. That trial did not continue.

Clinical Trials 59

Clinical Trials Epilepsy Pharmaceutical Treatment 59

TheAnswerPage

JANUARY 9, 2022

Has CBDV been evaluated as an anti-seizure medication in clinical trials? Yes, GW Pharmaceuticals (the makers of Epidiolex) had trialed CBDV in adult epilepsy, but the study did not meet its primary endpoint of seizure reduction. That trial did not continue.

Clinical Trials 59

Clinical Trials Epilepsy Pharmaceutical Treatment 59

Cannabis Law Report

NOVEMBER 16, 2021

Phase 2 trial recruiting begins immediately; efficacy data expected by the end of the first quarter of 2022. BALTIMORE–(BUSINESS WIRE)– MyMD Pharmaceuticals, Inc. About MyMD Pharmaceuticals, Inc. MyMD Pharmaceuticals, Inc. tumor necrosis factor receptor I (TNFRI) and IL-6.

Pharmaceutical 52

Pharmaceutical Clinical Trials Research and Development Therapy 52

TheAnswerPage

JULY 13, 2021

Has CBDV been evaluated as an anti-seizure medication in clinical trials? Yes, GW Pharmaceuticals (the makers of Epidiolex) had trialed CBDV in adult epilepsy, but the study did not meet its primary endpoint of seizure reduction. That trial did not continue.

Clinical Trials 59

Clinical Trials Epilepsy Pharmaceutical Treatment 59

Cannabis Law Report

NOVEMBER 23, 2021

BALTIMORE–(BUSINESS WIRE)– MyMD Pharmaceuticals, Inc. Nasdaq: MYMD) (“MyMD” or “the Company”), a clinical stage pharmaceutical company committed to extending healthy lifespan by delaying aging, announced that the U.S. About MyMD Pharmaceuticals, Inc. MyMD Pharmaceuticals, Inc.

Pharmaceutical 52

Pharmaceutical Clinical Trials Therapy Chronic Pain 52

Cannabis Law Report

JANUARY 5, 2022

BALTIMORE–(BUSINESS WIRE)– MyMD Pharmaceuticals, Inc. Nasdaq: MYMD) (“MyMD” or “the Company”), a clinical stage pharmaceutical company committed to extending healthy lifespan by delaying aging, announced that the U.S. About MyMD Pharmaceuticals, Inc. MyMD Pharmaceuticals, Inc.

Pharmaceutical 52

Pharmaceutical Clinical Trials Therapy Treatment 52

MMJ Recs

NOVEMBER 20, 2023

Epilepsy Management: CBD, in particular, has emerged as an effective treatment for epilepsy, especially in individuals with rare and severe forms of the condition. For example, the discovery of CBD’s effectiveness in managing epilepsy led to the development of Epidiolex, the first FDA-approved medication derived from marijuana.

Cannabinoids 98

Cannabinoids Epilepsy Treatment Marijuana 98

MedicalJane

OCTOBER 3, 2019

The United States Department of Defense and GW Pharmaceuticals are collaborating on a new clinical trial at the Montefiore Medical Center in New York. Dr. Eric Hollander, the Director of the Autism and Obsessive Compulsive Spectrum Program and Anxiety and Depression Program at Montefiore Hospital, is leading the clinical trial.

Clinical Trials 74

Clinical Trials Epilepsy Pharmaceutical Treatment 74

Cannabis Law Report

JANUARY 13, 2020

12, 2020 (GLOBE NEWSWIRE) — GW Pharmaceuticals plc (Nasdaq: GWPH), the world leader in the science, development, and commercialization of cannabinoid prescription medicines, today reported preliminary, unaudited net product sales for the fourth quarter and full-year 2019 and key priorities for 2020. Enquiries: GW Pharmaceuticals plc.

Pharmaceutical 66

Pharmaceutical Clinical Trials Research and Development Programs 66

Cannabis Law Report

DECEMBER 18, 2019

…MGC Pharmaceuticals has achieved yet another significant milestone with the bio-pharma company this week surpassing more than 1,800 prescribed products of its medicinal cannabis-based pharmaceutical products in Australia, UK, Brazil and Ireland. The West Australian reports. Source: [link].

Research and Development 59

Research and Development Clinical Trials Seed-To-Sale Pharmaceutical 59

Cannabis Law Report

JANUARY 10, 2022

This high share is attributable to the rising adoption of THCV for various applications such as epilepsy, arthritis, metabolic disorders, neurological disorders, and pain management. For instance, as of June 2021, InMed Pharmaceuticals, Inc., market for minor cannabinoids is anticipated to be valued at USD 26.2

Cannabinoids 52

Cannabinoids Clinical Trials Research and Development Supply Chain 52

Puff Puff Post

OCTOBER 3, 2019

Previous success from treating epilepsy with Cannabinoids now motivates doctors to investigate the plant’s effectiveness in treating symptoms of autism. Montefiore Medical Center in New York and GW Pharmaceuticals are examining the effects of a cannabis compound when administered to children on the autism spectrum.

Research and Development 94

Research and Development Epilepsy Clinical Trials Treatment 94

SpeedWeed

MARCH 30, 2021

Cannabis is no longer a dirty word, and, as it becomes a pharmaceutical product, doctors will then look upon it as a medicine,” Dr Couch added. Anthony Ordman is Honorary Medical Director of Integro Medical Clinics – one of the 20-plus private clinics to have emerged since the law change in 2018. Private Clinic Happy To Help. “By

Data 52

Data Patients Clinical Trials Business 52

Cannabis Law Report

SEPTEMBER 6, 2021

GW Pharmaceuticals. Clinical trials, research and development (R&D) activities and commercialization of cannabis-based indications are further expected to catalyze the growth of the market. GW Pharmaceuticals. 12 Overview of Clinical Research Suggesting the Benefits of Medical Cannabis Across Various Indications.

Chronic Pain 86

Chronic Pain Research and Development Clinical Trials Epilepsy 86

The Cannigma

MARCH 7, 2022

When CBN was studied without barbiturates (prescription sedative medications typically used for epilepsy), the combination of CBN and THC produced greater sedation together than either cannabinoid alone. What can the current clinical trials tell us?

THC 140

THC Sleep Clinical Trials Cannabinoids 140

Cannabis Law Report

NOVEMBER 1, 2021

A 2018 report by the World Health Organization said CBD showed no indication of potential abuse or dependence, and in fact it had been found in several clinical trials to be effective in treating epilepsy. Given the wide range of non-pharmaceutical CBD products, there may be other laws applicable to various products.

Wellness and Beauty 52

Wellness and Beauty CBD Clinical Trials Pharmaceutical 52

Veriheal

MARCH 23, 2023

Japan’s latest Cannabis Control Law revisions would apply to pharmaceutical-grade medicinal cannabis products. The report states that the revision is an essential move for ensuring the legal use of cannabis-derived epilepsy drug Epidiolex , which is currently being reviewed as part of a series of clinical trials in Japan.

Legalization 58

Legalization Marijuana Clinical Trials Seed-To-Sale 58

Kind Meds (Cannabis Education Blog)

NOVEMBER 18, 2020

For example, many anti-anxiety pharmaceuticals are habit-forming, entail significant negative side effects, and can also cause physical problems such as diminished mobility or coordination. Even doses higher than 1,000mg have been safely administered in testing, and CBD is considered safe for children for the treatment of epilepsy.

Treatment 111

Treatment Conditions CBD Clinical Trials 111

MedicalJane

JUNE 29, 2018

The FDA announced in a press release on Monday that it had approved the “first drug comprised of an active ingredient derived from marijuana to treat rare, severe forms of epilepsy.”. Use of CBD in seizure prevention is well-documented with research ; and now, after conducting its own trials, the FDA appears to agree.

Clinical Trials 53

Clinical Trials CBD DEA Research and Development 53

Cannabis Info

OCTOBER 11, 2019

Epidiolex is an epilepsy-fighting cannabis base drug produced by GW Prescription drugs. In Europe, there are round 50,000 young adults and children affected by one of many two signs of epilepsy. This approval is the fruits of a few years of dedication and collaboration between GW, physicians and the epilepsy neighborhood.

Business 45

Business Epilepsy Clinical Trials Treatment 45

Cannabis Law Report

MARCH 2, 2020

First up, cannabis has now been scientifically validated as a treatment for two severe forms of childhood epilepsy (more on this in a moment). Back in 2018, the DEA rescheduled GW Pharmaceuticals ‘ (NASDAQ: GWPH) cannabis-based epilepsy medicine, Epidiolex, following its regulatory approval by the FDA.

Medicine 59

Medicine Therapy DEA Pharmaceutical 59

Puff Puff Post

OCTOBER 3, 2019

Previous success from treating epilepsy with Cannabinoids now motivates doctors to investigate the plant’s effectiveness in treating symptoms of autism. Montefiore Medical Center in New York and GW Pharmaceuticals are examining the effects of a cannabis compound when administered to children on the autism spectrum.

Research and Development 40

Research and Development Epilepsy Clinical Trials Treatment 40

Cannabis Law Report

FEBRUARY 15, 2019

The Singapore Online Citizen reports… Law & Home Affairs Minister K Shanmugam says that pharmaceutical companies are hiding their intentions behind a smokescreen when it comes to cannabis. These can be administered through pharmaceutical products such as oral solutions and sprays. It‘s bunkum.”.

Medicine 45

Medicine Pharmaceutical Law Cannabinoids 45

Kind Meds (Cannabis Education Blog)

JANUARY 9, 2019

Medical marijuana laws have changed dramatically across the country in recent years, and now cannabis pharmaceuticals appear to be the next big leap forward in cannabis law reform. Epidiolex has received FDA approval to treat Dravet Syndrome and Lennox-Gestaut Syndrome; two very rare forms of epilepsy that manifest in early childhood.

Research and Development 97

Research and Development Treatment Pharmaceutical Conditions 97

Cannabis Law Report

JULY 13, 2019

clinical trials have been made by Members of Parliament. But it says one of the barriers to research is that industry is not always prepared to supply products for research trials. “We We heard throughout our inquiry that some pharmaceutical companies were not willing to provide their product for trial,” the report says.

Research and Development 40

Research and Development Clinical Trials Epilepsy Patients 40

Cannabis Law Report

NOVEMBER 29, 2019

For instance, THC has shown the potential to help in the treatment of conditions like PTSD, depression, eating disorders, and epilepsy. Although the FDA-approved pharmaceuticals change the receptor processes in the body, cannabis and THC work slightly differently. That’s why some people choose THC oil. THC Oil Benefits.

Oil 104

Oil THC Cannabinoids Research and Development 104

Cannabis Law Report

APRIL 10, 2019

MP Philippa Whitford (representing Central Ayrshire ), a doctor, called for more support for clinical trials so that doctors will be more willing to prescribe medical cannabis products: “That is quite scary for doctors, particularly as if it is an unlicensed drug, they have to sign a form to say that they accept personal liability.

Clinical Trials 51

Clinical Trials Epilepsy Medicine Research and Development 51

Cannabis Law Report

FEBRUARY 3, 2022

The presence of major key players, pharmaceutical and biotechnology industries worldwide, and their experimental approach drives the cannabis market growth. CBD oils have various health benefits in treating medical disorders like epilepsy, anxiety, cancer, acne, diabetes, and others. Clinical Trials of Cannabis Are Still on Going.

Indica 52

Indica Oil Legalization Research and Development 52

Veriheal

AUGUST 31, 2020

Essay Summary: Nishtha wants to further research into THC treatment for patients suffering from neurodegenerative diseases like Alzheimer’s and epilepsy , both of which cause neuron death. Essay: “Combining Social Sciences and Pharmacology to Make a Positive Social Impact in Cannabis” . School: University of Maryland.

Research and Development 117

Research and Development Education Agriculture Patients 117